1221446-17-8

Basic information

• Product Name: tert-butyl 8-(3-(1-acetyl-N-(3-chloro-4-methylphenyl)-4-piperidineformamide)propyl)-3-exo-8-azabicyclo[3.2.1]octan-3-carbamate
• Synonyms: tert-butyl 8-(3-(1-acetyl-N-(3-chloro-4-methylphenyl)-4-piperidineformamide)propyl)-3-exo-8-azabicyclo[3.2.1]octan-3-carbamate
• CAS NO: 1221446-17-8
• Molecular Weight: 561.165
• Mol File: 1221446-17-8.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: tert-butyl 8-(3-(1-acetyl-N-(3-chloro-4-methylphenyl)-4-piperidineformamide)propyl)-3-exo-8-azabicyclo[3.2.1]octan-3-carbamate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl 8-(3-(1-acetyl-N-(3-chloro-4-methylphenyl)-4-piperidineformamide)propyl)-3-exo-8-azabicyclo[3.2.1]octan-3-carbamate(1221446-17-8)
• EPA Substance Registry System: tert-butyl 8-(3-(1-acetyl-N-(3-chloro-4-methylphenyl)-4-piperidineformamide)propyl)-3-exo-8-azabicyclo[3.2.1]octan-3-carbamate(1221446-17-8)

Safety Data

• Hazardous Substances Data: 1221446-17-8(Hazardous Substances Data)

Upstream product

• 76272-34-9 8-Benzyl-1αH,5αH-nortropan-3-one Oxime 
• 28957-72-4 N-benzylnortropinone 
• 132259-54-2 exo-(8-benzyl-8-aza-bicyclo[3.2.1]oct-3-yl)-carbamic acid tert-butyl ester 
• 333985-70-9 1-acetyl-piperidine-4-carboxylic acid (3-chloro-4-methyl-phenyl)-(3-chloro-propyl)-amide 
• 132234-68-5 exo-3-<<(1,1-dimethylethoxy)carbonyl>amino>-8-azabicyclo<3.2.1>octane 
• 333985-68-5 (3-chloro-4-methyl-phenyl)-(3-chloro-propyl)-amine 
• 76272-36-1 8-benzyl-8-aza-bicyclo[3.2.1]oct-3-yl-amine 
• 28957-72-4 N-benzyltropinone 
• 24424-99-5 di-tert-butyl dicarbonate 
• 95-74-9 3-chloro-p-toluidine 
• 542-05-2 acetonedicarboxylic acid 
• 76272-34-9 8-benzyl-8-azabicyclo[3.2.1] octan-3-one oxime 

Downstream Products

• 1221446-18-9 1-acetyl-N-(3-(3-exo-amino-8-azabicyclo[3.2.1]oct-8-yl)propyl)-N-(3-chloro-4-methylphenyl)-4-piperidinylcarboxamide 
• 1221445-74-4 1-acetyl-N-(3-chloro-4-methylphenyl)-N-(3-(3-exo-(2-phenylacetamido)-8-azabicyclo[3.2.1]oct-8-yl)propyl)-4-piperidinylcarboxamide 
• 1221446-00-9 1-acetyl-N-(3-chloro-4-methylphenyl)-N-(3-(3-exo-benzyloxymethanamido-8-azabicyclo[3.2.1]oct-8-yl)propyl)-4-piperidinylcarboxamide 
• 1221446-01-0 1-acetyl-N-(3-chloro-4-methylphenyl)-N-(3-(3-exo-(methylsulfonylamido)-8-azabicyclo[3.2.1]oct-8-yl)propyl)-4-piperidinylcarboxamide 
• 1221446-07-6 1-acetyl-N-(3-chloro-4-methylphenyl)-N-(3-(3-exo-(3-(4-methoxylphenyl)ureylene)-8-azabicyclo[3.2.1]oct-8-yl)propyl)-4-piperidinylcarboxamide 

Relevant articles and documents

Bifunctional Chimera That Coordinately Targets Human Immunodeficiency Virus 1 Envelope gp120 and the Host-Cell CCR5 Coreceptor at the Virus-Cell Interface

To address the urgent need for new agents to reduce the global occurrence and spread of AIDS, we investigated the underlying hypothesis that antagonists of the HIV-1 envelope (Env) gp120 protein and the host-cell coreceptor (CoR) protein can be covalently joined into bifunctional synergistic combinations with improved antiviral capabilities. A synthetic protocol was established to covalently combine a CCR5 small-molecule antagonist and a gp120 peptide triazole antagonist to form the bifunctional chimera. Importantly, the chimeric inhibitor preserved the specific targeting properties of the two separate chimera components and, at the same time, exhibited low to subnanomolar potencies in inhibiting cell infection by different pseudoviruses, which were substantially greater than those of a noncovalent mixture of the individual components. The results demonstrate that targeting the virus-cell interface with a single molecule can result in improved potencies and also the introduction of new phenotypes to the chimeric inhibitor, such as the irreversible inactivation of HIV-1.

AMIDE COMPOUNDS, THEIR PHARMACEUTICAL COMPOSITIONS, THEIR PREPARATION METHOD AND THEIR USES

The present invention pertains to the field of pharmaceutical chemistry and discloses 8-(3-aminopropyl)-3-exo-8-azabicyclo[3.2.1]octane-3-amino amide compounds represented by formula I, the pharmaceutical compositions, the preparation method and the use thereof. Such compounds or pharmaceutically acceptable salts thereof can be used as an antagonist of CCR5 in preparing medicaments for treating diseases mediated by CCR5, particularly HIV infection, asthma, rheumatoid arthritis, autoimmune diseases and chronic obstructive pulmonary diseases (COPD).